Samsung Biologics Completes Acquisition of GSK's U.S. Plant
Samsung Biologics has officially acquired a biopharmaceutical manufacturing plant in Rockville, Maryland, marking its first production foothold in the United States, following its announced acquisition of a U.S. facility from GSK for US$280 million.
The Story
Analyzing sources…
Source Diversity
Source Diversity
Low (19/100)Sources
Samsung Biologics completes GSK US plant deal
Samsung Biologics has officially acquired a biopharmaceutical manufacturing plant in Rockville, Maryland, to signify its first production foothold in the United States, the company said Wednesday. The Korean contract development and manufacturing organization, or CDMO, announced the $280 million deal to acquire GSK’s plant in Rockville in December. The newly added site features two Current Good Manufacturing Practice, or cGMP-certified, manufacturing plants with a combined 60,000-liter drug subs
By The Korea Herald
Read full article →Samsung Biologics acquires GSK's U.S. facility for US$280 mln - Yonhap News Agency
Samsung Biologics acquires GSK's U.S. facility for US$280 mln Yonhap News Agency
Read full article →
